Insulin degludec - Jiangsu Hengrui Medicine
Alternative Names: INS-068; INS068 injection; Insulin degludec me-betterLatest Information Update: 28 Oct 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in China (SC)
- 18 Jul 2023 Jiangsu HengRui Medicine completes a phase I trial for Diabetes mellitus (In volunteers) in China (SC) (NCT05887895)
- 05 Jun 2023 Jiangsu HengRui Medicine plans a phase I trial for Diabetes mellitus (In volunteers) in May 2023 (SC, Injection) (NCT05887895)